Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A new study, published in Science Translational Medicine by researchers at the University of Oxford has identified that Talarozole, a drug that is known to increase retinoic acid, was able to prevent osteoarthritis (OA) in disease models.

Doctor examining hand of patient with rheumatoid arthritis © SHUTTERSTOCK

Tonia Vincent, Professor of Musculoskeletal Biology & Honorary Rheumatologist at Oxford’s Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), said: ‘Hand osteoarthritis is a common and debilitating medical condition that affects mainly women, especially around the time of the menopause. We currently have no effective treatments that modify their disease.’

The researchers started by investigating a common gene variant that had been linked to severe hand OA. Using patient samples collected at the time of routine hand surgery, as well as a number of experimental models, they were able to identify a key molecule that was especially low in ‘at risk’ individuals, called retinoic acid.

More than 40% of individuals will develop osteoarthritis (OA) during their lifetime. Hand (OA) is an extremely common form of OA and there are currently no disease modifying treatments that effectively relieve symptoms or stop deformity and stiffness of the joints.

Professor Vincent added: ‘This project was only possible because of the multi-disciplinary approach that we took; working with our hand surgical colleagues, geneticists, data scientists and biologists.’

As talarozole has an acceptable safety profile in human subjects, a small proof of concept clinical study is underway to see whether this drug might represent a new disease modifying treatment in patients.

Dr Neha Issar-Brown, Director of Research and Health Intelligence at the charity Versus Arthritis, which funded the research, said: ‘Around 8.5 million people in the UK live with OA. Despite often being dismissed as just a few aches and pains, OA can have a profound and far-reaching impact on life, affecting people's ability to work, care for a family, or live independently.

‘There is an urgent need for disease-modifying treatments designed to prevent or reverse the painful symptoms of OA. This study reveals a new understanding of the causes of hand osteoarthritis, which could lead to identifying new biological targets for intervention in hand OA.

‘This research is still at an early stage, but with these encouraging findings we are a big step closer in being able to develop a new class of disease-modifying drugs to treat osteoarthritis, prevent chronic pain, and enable people to live well with the condition,’ Dr Issar-Brown concludes.

Similar stories

Sara Khalid named Associate Professor at NDORMS

The University of Oxford has awarded the title of Associate Professor to Dr Sara Khalid as part of its recognition of excellence awards.

Max Stewart awarded an MRC fellowship

A DPhil candidate at NDORMS, Max received the MRC Clinical Research Training Fellowship to further his research into finding new treatments for peripheral nerve injuries.

The new Botnar strategy is announced

After a year as the Director of the Botnar Institute for Musculoskeletal Sciences, Professor Jonathan Rees announces a new structure and strategy that will further enhance research and treatment of bone, joint and musculoskeletal conditions.

New global health grant to improve outcomes for patients with hip fracture

Hip fracture patients in Low- and Middle-Income Countries (LMIC) in Asia are set to benefit from a new study that aims to bring best practice programmes to improve quality of life for patients and reduce healthcare costs.

NDORMS welcomes great-granddaughter of former Head of Department

Julia Strubell, great-granddaughter of Professor Josep Trueta, visited NDORMS to find out about his time here and to share her own work with staff and students.

Botnar researchers awarded Fellowships

Arani Vivekanantham has been awarded an NIHR Doctoral Fellowship and a Versus Arthritis Clinical Research Fellowship, and Rachel Kuo was awarded an NIHR Doctoral Research Fellowship.